# Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

> **NCT03078751** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 54 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Ribociclib
- **DRUG:** Adjuvant endocrine therapy
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03078751
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-20
- **Primary completion:** 2020-03-09
- **Final completion:** 2020-03-09
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2021-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03078751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03078751, "Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03078751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*